Catalyst Pharmaceuticals (zynerbac) is up 12% in premarket trading on Friday, bringing its market cap to $19.5bn.
The stock has been trending up since the start of the year.
The company announced in January that it was launching a treatment for a rare and aggressive form of cancer called Rheumatoid Arthritis.
The company has also announced it will launch a $1bn biotechnology business in the US in the next few weeks.
Zynerba has also been trading up in the past few days.
The stock hit a new all-times high of $1.29 on Thursday, after a bullish outlook from analysts and investors.ZYNERBAC has seen its share price go up on a lot of occasions.
In January, it hit a record high of nearly $2.40 per share and then dropped to $1,266.60 on Thursday.
The share price was trading at $1.,262 on Thursday before it went all the way down to $876.55 on Friday.
The company said it will continue to focus on the Rheumatic Diseases and cancer treatments and that it has been able to achieve significant growth in the industry.
The news comes on the heels of Zynerbax Pharmaceuticals, which is up nearly 30% on Friday in pre-market trading.
Zynerbs earnings report also fell short of expectations.